Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.

CONCLUSION: Sacituzumab govitecan is a novel targeted treatment with promising activity in mTNBC.
PMID: 33070624 [PubMed - as supplied by publisher]

Source: The Annals of Pharmacotherapy - October 17, 2020 Category: Drugs & Pharmacology Authors: Seligson JM, Patron AM, Berger MJ, Harvey RD, Seligson ND Tags: Ann Pharmacother Source Type: research